KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity (2016 - 2025)

Historic Common Equity for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $917.3 million.

  • Acadia Pharmaceuticals' Common Equity rose 5892.3% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 5892.3%. This contributed to the annual value of $732.8 million for FY2024, which is 6972.43% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Common Equity of $917.3 million as of Q3 2025, which was up 5892.3% from $822.4 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Common Equity high stood at $917.3 million for Q3 2025, and its period low was $362.2 million during Q3 2023.
  • In the last 5 years, Acadia Pharmaceuticals' Common Equity had a median value of $516.7 million in 2024 and averaged $543.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 2597.2% in 2022, then skyrocketed by 6972.43% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Common Equity stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then rose by 7.83% to $431.8 million in 2023, then soared by 69.72% to $732.8 million in 2024, then increased by 25.17% to $917.3 million in 2025.
  • Its last three reported values are $917.3 million in Q3 2025, $822.4 million for Q2 2025, and $765.2 million during Q1 2025.